The pharmaceutical industry is sitting on a quiet revolution. Over the past decade, historical clinical and preclinical datasets have evolved from dusty archives into strategic assets that fundamentally reshape how we design trials, calculate statistics, and make billion-dollar R&D decisions.And here’s what makes this shift so powerful: we’re no longer flying blind.
When a Director of Clinical Development at a mid-sized biotech needs to design a Phase 2 oncology trial, they’re not starting from scratch. They’re tapping into decades of aggregated data—control arm outcomes, event rates, dropout patterns, adverse event frequencies—that transform guesswork into evidence-based protocol development. The same datasets that once required months of literature review are now queryable, analyzable, and ready to inform decisions in days.
But accessing and leveraging these datasets effectively? That’s where most organizations hit a wall.
Why Historical Clinical and Preclinical Datasets Matter More Than Ever
The economics of drug development are brutal. We’re looking at a 90% attrition rate from Phase 1 to approval, with costs per approved drug exceeding $2.6 billion when you factor in failures. Every percentage point improvement in success probability translates to hundreds of millions in expected value.
This is why smart R&D teams have shifted their approach to historical data entirely.
Clinical trial datasets—aggregated from past studies across therapeutic areas—provide the empirical foundation for virtually every aspect of protocol development. When biostatisticians calculate sample sizes for cardiovascular outcomes trials, they’re building on decades of historical event rate data. When clinical operations teams assess feasibility, they’re benchmarking against real enrollment curves from similar indications.
The applications span the entire development lifecycle:
Trial Design & Protocol Development. Historical datasets enable evidence-based decisions on endpoints, inclusion criteria, randomization schemes, and adaptive designs. Instead of conservative assumptions that inflate sample sizes, teams can use historical benchmarks to right-size studies—reducing both cost and patient exposure to placebo.
Biostatistical Analysis & Historical Borrowing. Modern Bayesian approaches incorporate historical data as informative priors, effectively “borrowing strength” from past studies. The meta-analytic-predictive (MAP) prior methodology developed by Schmidli and colleagues has become standard practice in oncology and rare diseases, where every patient counts.
R&D Portfolio Strategy. Preclinical datasets—from in vitro assays to animal models—inform translational predictions. When a Chief Scientific Officer needs to prioritize three competing oncology assets, aggregated preclinical PK/PD data provides the quantitative backbone for go/no-go decisions. Leading pharmaceutical companies have pioneered open innovation datasets specifically to enable better cross-industry learning from preclinical failures.
Synthetic Patient Modeling. This is where things get really interesting. Advanced platforms generate artificial patient profiles that mimic real clinical characteristics—enabling simulation of rare disease trials or augmentation of limited datasets without privacy constraints. The validation work by Azizi and colleagues demonstrated that properly constructed synthetic datasets can serve as reasonable proxies for certain trial simulations.
The FDA’s Growing Embrace of Model-Informed Drug Development
Regulatory acceptance has been the game-changer here.
The FDA’s Model-Informed Drug Development (MIDD) Pilot Program explicitly encourages using historical and external data to inform trial design and analysis. Their 2023 guidance on externally controlled trials provides a clear framework for when and how historical controls can replace concurrent controls—a massive opportunity in rare diseases where randomization is ethically or practically challenging.
As of 2026, we’re seeing increasing acceptance of external control arms in regulatory submissions, particularly in oncology and rare diseases. Hey and Kimmelman’s analysis of FDA decision-making showed that external controls contributed to approval decisions in 16% of analyzed cases—and that proportion is growing.
The International Council for Harmonisation (ICH) has followed suit with M15 guidance on MIDD principles, harmonizing expectations across major regulatory authorities. This isn’t fringe methodology anymore… it’s becoming standard practice for evidence-informed development.
Real Applications Across Drug Development Stages
Early Development and Preclinical Translation
Preclinical datasets serve a critical bridging function between discovery and first-in-human studies. Historical in vitro data, animal PK/PD profiles, and toxicology benchmarks inform starting dose selection and predict human exposure-response relationships.
The challenge? Most preclinical data remains siloed within organizations. When you’re selecting a starting dose for a first-in-human oncology trial, you’re often working from your internal data plus whatever snippets appear in published literature. But aggregated preclinical databases—when available—allow benchmarking across compound classes, identifying outliers, and refining translational models.
Computational approaches now leverage these datasets for in silico predictions. Physiologically-based pharmacokinetic (PBPK) modeling uses historical human and animal PK data to simulate human exposure before dosing a single patient. Quantitative systems pharmacology (QSP) models integrate preclinical mechanism data to predict clinical efficacy.
Clinical Trial Design and Feasibility
This is where historical clinical datasets show immediate ROI.
When designing a Phase 3 cardiovascular outcomes trial, teams need to estimate event rates (MI, stroke, cardiovascular death) for sample size calculations. Historical datasets from similar populations provide empirical distributions—not just point estimates but variability, subgroup differences, and time-to-event patterns.
The same data informs feasibility assessments. If your inclusion criteria require HbA1c > 8.5% and eGFR 30-60, historical datasets show how restrictive that combination is and predict screening ratios. This prevents the all-too-common scenario where trials enroll for twice as long as planned because the protocol was theoretically elegant but practically infeasible.
Adaptive trial designs rely heavily on historical data for simulation and planning. Madabushi and colleagues’ review highlighted how dose-response modeling using historical Phase 2 data enables seamless Phase 2/3 designs with interim adaptation—reducing overall development time by 1-2 years in some therapeutic areas.
Biostatistics and Historical Borrowing
Modern biostatistical approaches have moved beyond simple frequentist analyses to sophisticated Bayesian methods that formally incorporate historical information.
The concept is straightforward: if you have high-quality historical control data from similar populations, why ignore it? Incorporating that information as a prior distribution allows you to reduce the concurrent control group size—or in some cases, eliminate it entirely through an external control design.
But the devil is in the details. Historical data must be carefully evaluated for comparability—patient characteristics, standard of care, outcome assessment, and unmeasured confounders all matter. Thorlund and colleagues’ primer on synthetic and external controls emphasizes the importance of propensity score matching, covariate adjustment, and sensitivity analyses to address potential bias.
The MAP prior approach allows dynamic borrowing based on similarity. If historical data align closely with concurrent controls, the method borrows more information. If there’s heterogeneity, it automatically down-weights historical data. This adaptive borrowing provides a principled middle ground between ignoring historical data and uncritically pooling it.
R&D Strategy and Portfolio Decisions
Beyond individual trial design, aggregated datasets inform strategic portfolio decisions that determine which assets advance and which get shelved.
Consider a scenario where you have three early-stage oncology assets targeting different mechanisms in non-small cell lung cancer. Historical Phase 2 data across mechanism classes, combined with preclinical predictive biomarker performance, allows quantitative modeling of probability of success. Instead of gut-feel decisions, you’re building probabilistic models that integrate historical benchmark data.
Biotech companies increasingly use historical clinical datasets to identify white space opportunities—indications where current standard of care shows suboptimal outcomes in real-world data, suggesting unmet medical need. This same data informs competitive intelligence: understanding how competitor products perform in real-world settings versus their trial populations.
Synthetic Data and In Silico Trials
Synthetic data generation represents the frontier of how we’re using historical datasets.
The core idea: use generative models (GANs, VAEs) trained on real patient data to create artificial patient profiles that preserve statistical properties without containing actual patient information. These synthetic cohorts can then be used for trial simulations, protocol testing, or—controversially—as control arms.
The advantages are significant. Privacy-preserving by design. Unlimited sample sizes for rare populations. Ability to generate “what-if” scenarios (e.g., what if we excluded patients with baseline characteristic X?). Training machine learning models without re-identification risk.
But synthetic data also has limitations that need acknowledging. Current methods struggle to capture complex multivariate relationships and rare edge cases. Validation remains challenging—Azizi’s validation study showed good concordance for common outcomes but noted limitations for rare events. Regulatory acceptance as primary evidence remains limited, though use for simulation and planning is well-accepted.
Recent work on synthetic control arms in hematological malignancies by Selukar and colleagues shows the maturation of this approach in therapeutic areas where randomization is particularly challenging.
Navigating the Data Landscape: What to Look For
So here’s the uncomfortable truth: despite all this potential, most organizations struggle to actually access and use high-quality aggregated datasets effectively.
The challenge many pharmaceutical companies face isn’t finding data sources—it’s determining which combination of capabilities aligns with their strategic priorities and specific use cases.
Data Sharing Remains Limited. Public platforms like Vivli, TransCelerate BioPharma, and the Yale Open Data Access (YODA) Project have made progress, but the majority of historical trial data remains locked in company databases or available through commercial sources. Yin and colleagues documented that less than 5% of trial data is routinely shared despite growing commitments from large pharma.
Why? Competitive concerns, resource intensity of preparing data for sharing, liability worries, and frankly, lack of clear incentives. Preparing trial data for external sharing—anonymization, documentation, metadata standardization—costs hundreds of thousands of dollars per trial with minimal direct return.
Heterogeneity Across Sources. Even when you can access multiple datasets, integrating them is a nightmare. Different CDISC versions, non-standard variable definitions, inconsistent endpoint adjudication, varying levels of detail on covariates… the data engineering burden often exceeds the analysis burden.
Academic trial data is particularly problematic—often collected without commercial standards, lacking the rigorous documentation that enables reuse. Real-world data sources add another layer of complexity with unstructured fields and incomplete outcome capture.
Quality and Completeness Vary Dramatically. Historical datasets may lack key variables (biomarkers weren’t collected because the test didn’t exist), have systematic biases (predominantly Western populations), or reflect outdated standards of care. Using 2015 control arm data for a 2026 trial design requires careful consideration of what’s changed in standard management.
The Expertise Gap. Properly leveraging historical data requires specialized biostatistical expertise that many organizations lack. MAP priors, propensity scoring, sensitivity analyses for unmeasured confounding—these aren’t skills every biostatistician possesses. And getting it wrong leads to biased conclusions or regulatory pushback.
Key Evaluation Dimensions for Data Partnerships
When evaluating potential data sources for your clinical development programs, several critical dimensions separate adequate from excellent partnerships:
Coverage and Granularity. Some sources maintain comprehensive longitudinal records covering hundreds of millions of patient lives across multiple regions and therapeutic areas. Others specialize in specific populations (rare diseases, oncology, cardiovascular) with greater depth. The choice depends on whether you need breadth for epidemiology work or depth for specific indication intelligence.
Data Recency and Update Frequency. Capabilities range from adjudicated historical data (18-24 month lag) to near real-time feeds. For competitive intelligence and launch tracking, recency matters. For historical controls in trial design, validated adjudicated data often provides better quality despite the lag.
Analytical Sophistication. Options span from raw data delivery requiring significant internal processing to full-service analytics platforms with pre-built models. Some sources provide self-service query tools, while others operate on a custom analytics model. Your internal capabilities and use cases determine the right balance.
Data Integration and Enrichment. Some providers combine trial data with complementary information sources—real-world data, molecular profiling, outcomes registries—creating richer analytical possibilities. This integration can be critical for translational research bridging preclinical and clinical stages.
Compliance and Documentation. GDPR compliance, data provenance documentation, validation processes, and audit trails vary significantly. For regulatory submissions using historical controls, this documentation isn’t optional—it’s the difference between acceptance and rejection.
Understanding which combination of these capabilities matches your specific needs requires deep market knowledge that most companies lack internally. The gap between understanding what clinical datasets can do and identifying which specific sources match your requirements is substantial.
Emerging Trends Reshaping the Landscape
Despite these challenges, several trends are accelerating the strategic value of clinical and preclinical datasets:
AI-Driven Data Harmonization. Machine learning approaches are automating previously manual data standardization tasks. Natural language processing extracts information from unstructured fields. Automated covariate mapping reduces integration time from months to weeks.
Federated Analytics Platforms. Rather than centralizing sensitive data, federated approaches allow queries to run locally with only aggregate results shared. This addresses privacy concerns while enabling cross-database insights.
Regulatory Harmonization. The FDA’s MIDD program, EMA’s qualification opinions on methodologies, and ICH M15 guidance are creating aligned expectations across authorities. This reduces uncertainty and encourages investment in these approaches.
Industry Consortia. TransCelerate BioPharma’s initiatives on historical controls, CDISC’s standardization work, and therapeutic area-specific data sharing (e.g., Project Data Sphere in oncology) are expanding the available evidence base.
Specialized Data Curation Services. Organizations focusing on curating, standardizing, and providing access to aggregated clinical datasets are filling the gap between public repositories and proprietary internal data. These services typically offer cleaned, analysis-ready data with comprehensive documentation—dramatically reducing time-to-insight.
Practical Considerations for Implementation
If you’re considering incorporating historical or preclinical datasets into your development strategy, here’s what actually works:
Start with Clear Use Cases. Don’t boil the ocean. Identify specific high-value applications: sample size reduction for a rare disease program, external control for an ultra-rare indication, or historical benchmarking for Phase 2 decision criteria. Build expertise and credibility with wins before tackling complex applications.
Define Requirements Before Evaluating Options. Document your coverage needs (geographies, therapeutic areas, patient populations), analytical capabilities (self-service vs. full-service), integration requirements (API access, data formats), compliance constraints, and budget parameters. This clarity prevents costly mismatches between what you need and what you license.
Invest in the Right Expertise. This requires specialized biostatistical knowledge. Consider hiring or consulting with experts who have regulatory experience with these methods. Galluppi’s practical considerations for MIDD paired meetings emphasize the importance of early regulatory engagement.
Prioritize Data Quality Over Volume. Ten well-documented, high-quality historical trials are worth more than 100 poorly documented ones. Focus on sources with comprehensive covariate capture, clear outcome definitions, and validation documentation.
Leverage Expert Guidance for Source Selection. The clinical and preclinical data landscape includes dozens of potential sources with overlapping but distinct capabilities. Navigating this complexity requires expertise in both pharmaceutical development and the evolving data ecosystem. Expert advisors who understand both your business objectives and the available options can accelerate your path to value while avoiding common pitfalls that lead to expensive licensing agreements that don’t deliver expected insights.
Engage Regulators Early. For any novel application of historical or external data, pre-submission meetings are essential. Regulators are generally supportive when the scientific rationale is sound and limitations are acknowledged, but surprises at submission lead to delays.
Build Internal Infrastructure. Establish processes for evaluating data source quality, standardizing internal historical data, and documenting decisions around historical borrowing. Create institutional knowledge rather than one-off projects.
Pilot Before Scaling. Start with a focused project to validate that your chosen approach answers your questions before committing to large-scale licensing agreements. This reduces risk and builds internal confidence in the methodology.
The ROI of Getting This Right
When executed well, leveraging historical clinical and preclinical datasets delivers measurable business impact.
Sample size reductions of 20-40% through Bayesian historical borrowing translate directly to cost savings—easily $5-10M per Phase 3 trial. Shortened enrollment timelines accelerate market entry by 6-12 months, worth hundreds of millions in peak sales for commercial assets.
Improved trial success rates through better design and feasibility assessment reduce the overall cost of failures. Even a 5 percentage point improvement in Phase 3 success probability has massive portfolio-level value given the economics of attrition.
For rare disease programs where recruitment is the rate-limiting step, external controls can mean the difference between a feasible trial and an impossible one. This enables entry into therapeutic areas previously considered too challenging.
The strategic advantage extends beyond individual programs. Organizations that build mature capabilities in historical data utilization make faster, more informed portfolio decisions. They identify opportunities competitors miss. They design trials that regulators embrace rather than question.
Looking Ahead: The Future of Evidence-Informed Development
We’re moving toward a future where historical evidence isn’t an afterthought—it’s integrated throughout development.
Imagine a scenario in 2028: Your team is designing a Phase 2 trial in an orphan indication. Before writing the protocol, an AI-powered platform analyzes 50,000 historical trials, identifies the 40 most similar past studies, and provides empirical distributions for every key parameter. It flags design elements associated with operational challenges in similar populations. It simulates 10,000 trial scenarios using synthetic patients generated from historical data, identifying optimal enrollment criteria and sample size.
That’s not science fiction—the building blocks exist today. What’s missing is integration, accessibility, and organizational readiness to adopt these approaches systematically rather than opportunistically.
The regulatory environment is ready. The methodology is mature. The economic incentives are overwhelming. The rate-limiting factors are organizational change, internal expertise development, and access to high-quality, appropriately matched data sources.
Common Questions from Clinical Development Teams
How do we know if historical data is appropriate for our specific trial?
Start with a structured comparability assessment: patient population characteristics, standard of care, outcome definitions, and data collection methods. Statistical tests for heterogeneity help quantify similarity. When in doubt, use historical data for simulation and planning rather than primary analysis—there’s still value even without formal borrowing.
What level of documentation do regulators expect for external control designs?
Extensive. You’ll need to justify data source selection, document inclusion/exclusion criteria for historical patients, provide covariate balance tables, conduct sensitivity analyses for unmeasured confounding, and address any potential biases. The FDA’s 2023 guidance provides a detailed framework. Plan for this documentation from the start—retrofitting is painful.
Can synthetic data replace real control arms?
Not yet for primary regulatory evidence, though acceptance is growing in specific contexts. Synthetic controls work best as supplementary evidence or for simulation/planning. The field is evolving rapidly—recent work in hematological malignancies shows promising validation, but expect regulatory skepticism for novel applications.
How much does historical data actually improve success rates?
Hard to quantify precisely, but evidence is accumulating. MIDD approaches have been associated with shorter development timelines and higher approval rates in recent FDA analyses. The real value often isn’t just success probability—it’s failing faster when failure is inevitable, or identifying feasibility issues before investing in doomed studies.
What about data privacy and GDPR compliance?
Properly anonymized historical datasets don’t contain personal data under GDPR, but the definition of “properly anonymized” is strict. Work with legal counsel and data protection experts. For European data, pay special attention to secondary use consent and data transfer mechanisms. Reputable data sources should provide comprehensive compliance documentation.
How do we evaluate different data sources for our specific needs?
This requires a structured evaluation framework covering coverage, data quality, analytical capabilities, compliance documentation, cost models, and support services. Most companies underestimate the complexity of this evaluation—the dimensions that matter vary significantly by use case, and the trade-offs aren’t always obvious. Expert guidance from advisors who understand both your business objectives and the data landscape can prevent costly mismatches between what you license and what you actually need.
Next Steps: Building Your Historical Data Strategy
If you’re convinced that historical clinical and preclinical datasets should play a larger role in your development strategy, here’s a pragmatic roadmap:
Assess Your Current State. Inventory what historical data you already have internally. Identify programs where external data could add value—rare diseases, areas with recruitment challenges, or where competitors have established benchmarks you need to understand.
Define Your Requirements Clearly. Before evaluating specific options, document exactly what you need: therapeutic areas, patient populations, data elements, analytical capabilities, compliance requirements, and budget constraints. This requirements definition process often surfaces considerations you hadn’t initially recognized—expert consultants can help structure this phase to ensure you’re comparing options on dimensions that actually matter for your use cases.
Build or Acquire Expertise. This isn’t optional. Either develop internal capabilities through training and hiring, or establish relationships with specialist consultants and advisors. Half-measures lead to poorly designed applications that regulators question or licensing agreements that don’t deliver value.
Understand Your Options. The landscape of available data sources is complex and constantly evolving. Options range from public repositories to specialized commercial sources, each with distinct strengths. Understanding which combination of capabilities matches your needs requires expertise in both pharmaceutical development and the data ecosystem.
Start with a Pilot. Choose a medium-complexity application—perhaps historical benchmarking for go/no-go criteria or MAP priors for sample size determination in a Phase 2. Learn the operational realities before tackling mission-critical Phase 3 applications.
Engage Regulators Proactively. For any novel application, seek feedback through qualification advice, Type C meetings, or MIDD paired meetings. This de-risks your approach and often surfaces helpful methodological suggestions.
Invest in Infrastructure. Build systems for evaluating data quality, documenting decisions, and maintaining institutional knowledge. The goal is repeatable processes, not heroic one-off efforts.
The pharmaceutical industry is increasingly evidence-informed rather than intuition-driven. Historical clinical and preclinical datasets are the foundation of that transformation—enabling smarter trial design, more efficient development, and ultimately, faster delivery of medicines to patients who need them.
The question isn’t whether your organization will adopt these approaches. It’s whether you’ll be an early mover capturing competitive advantage, or a late follower playing catch-up.
Expert Guidance for Strategic Implementation
Navigating the landscape of clinical and preclinical datasets requires expertise in both pharmaceutical development and the evolving real-world evidence ecosystem. Understanding what types of data exist and what questions they can answer is the first step. The second step—matching your requirements to the right combination of data sources, analytical capabilities, and domain expertise—requires guidance from professionals who understand both the pharmaceutical industry and the available options.
The gap between licensing datasets and extracting actionable intelligence is substantial. Expert advisors can help you:
- Structure your requirements definition to capture all critical dimensions
- Evaluate the trade-offs between different data models and analytical approaches
- Navigate compliance and regulatory considerations for your specific use cases
- Avoid common pitfalls that lead to expensive agreements that underdeliver
- Build internal capabilities for sustained competitive advantage
Most companies underestimate the complexity of getting this right. The vendors available are numerous, their capabilities overlap in confusing ways, and the decision criteria that matter vary significantly by use case. This is where expert guidance becomes critical—accelerating your path to value while avoiding costly mismatches.
Ready to explore how clinical and preclinical datasets can transform your development strategy?
Contact MEDDDICAL to discuss your specific requirements and explore strategic approaches to evidence-informed drug development that align with your business objectives.
Sources & References
- Madabushi R, et al. (2022). Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making. Clinical Pharmacology & Therapeutics. https://pmc.ncbi.nlm.nih.gov/articles/PMC9097888/
- Thorlund K, et al. (2020). Synthetic and External Controls in Clinical Trials – A Primer for Researchers. Clinical Epidemiology. https://pubmed.ncbi.nlm.nih.gov/32440224/
- Viele K, et al. (2014). Use of historical control data for assessing treatment effects in clinical trials. Pharmaceutical Statistics. (Foundational work widely cited in subsequent literature on historical borrowing methodologies.)
- Schmidli H, et al. (2014). Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics. https://doi.org/10.1111/biom.12242
- Hey SP, Kimmelman J. (2021). The Use of External Controls in FDA Regulatory Decision Making. Clinical Pharmacology & Therapeutics. https://pmc.ncbi.nlm.nih.gov/articles/PMC8332598/
- Azizi Z, et al. (2021). Can synthetic data be a proxy for real clinical trial data? A validation study. BMJ Open. https://bmjopen.bmj.com/content/11/4/e043497
- Galluppi GR, et al. (2024). Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program. Clinical Pharmacology & Therapeutics. (Practical industry perspective on engaging with FDA’s MIDD program.)
- Marshall SF, et al. (2016). Model-informed drug development: a rational approach to drug development. Clinical Pharmacology & Therapeutics. (Seminal review establishing core MIDD principles adopted by regulators.)
- U.S. Food and Drug Administration (2023). Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products. Guidance for Industry. https://www.fda.gov/media/164960/download
- U.S. Food and Drug Administration (2024). M15 General Principles for Model-Informed Drug Development; International Council for Harmonisation; Draft Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m15-general-principles-model-informed-drug-development
- Yin Y, et al. (2019). Sharing Historical Trial Data to Accelerate Clinical Development. Clinical Pharmacology & Therapeutics. https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1608
- Selukar S, et al. (2025). Synthetic control arms and other uses of external data in clinical trials for hematological malignancies. Blood Reviews. https://pubmed.ncbi.nlm.nih.gov/40753019/